summary

• APA-RP (NCT04523207) was a phase 2, open-label, single-arm, multicenter study that evaluated the efficacy and safety of adjuvant treatment with ERLEADA and androgen deprivation therapy (ADT) in treatment-naïve patients with high-risk localized prostate cancer who have undergone radical prostatectomy (RP; N=108).^1,2
• Use of a prespecified rash management guide outlining proactive steps for medical management of rash and patient education on gentle skin care was implemented for patients enrolled in the study, with the intent to reduce the onset and severity of rash events. Rash-related safety data were collected during the first 12 months following initation of ERLEADA treatment and compared descriptively with the North American patient populations of the global SPARTAN and TITAN studies.³
• The infographic on pages 2-3 provide the rash management guide and the rash-related safety data results.

Rash Management Guide